bicalutamide / Generic mfg. - LARVOL DELTA

Case Report: Stable disease achieved in a patient with metastatic castration-resistant prostate cancer following personalized treatment. (PubMed, Front Oncol) - "Here, we shared a mCRPC patient who achieved stable disease after treatment with the drugs sensitive in organoid drug screening, despite failure in previous several standard therapies. This typical case highlights that prostate cancer organoids may serve as a potential companion tool to optimize treatment options and improve treatment outcomes, thus realizing the personalized management of mCRPC patients, especially those exhausting the standard therapies."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Drug utilisation evaluation of oral anticancer therapy in a south indian cancer centre (ESMO Asia 2025) - "Among targeted therapies, Gefitinib, Osimertinib, Crizotinib, Afatinib, Lorlatinib, and Nilotinib demonstrated consumption of 30 DDDs per patient over 30 days. Lower consumptions were observed with Lenvatinib and Cabozantinib with 13.3 DDDs and 11.25 DDDs per patient respectively. In the hormonal therapy group, Letrozole, Tamoxifen, Bicalutamide, Anastrozole, Enzalutamide, and Exemestane were all prescribed in line with WHO standards (30 DDDs per patient), whereas Abiraterone exhibited lower consumption of 15 DDDs per patient. Prescribing patterns and consumption metrics were largely consistent with WHO criteria, indicating rational oral anticancer drug use. Prescribing patterns and consumption metrics were largely consistent with WHO criteria, indicating rational oral anticancer drug use. Dose deviations occurred, though reasons were unclear and may relate to adverse effects, indication-specific or patient factors, or economic constraints. Further research is warranted..."

Oncology • Oral Cancer

NRG-GU002: Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (clinicaltrials.gov) - P2/3 | N=612 | Completed | Sponsor: NRG Oncology | Active, not recruiting ➔ Completed | Trial completion date: May 2026 ➔ Oct 2025 | Trial primary completion date: May 2026 ➔ Oct 2025

Trial completion • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Development and optimization of Soluplus®/Pluronic-based polymeric micelles for bicalutamide delivery: characterization, lyophilization, stability, and cellular studies. (PubMed, Eur J Pharm Sci) - "F7 exhibited superior cytotoxicity among the tested formulations, compared to free BIC, while its blank formulation showed no significant toxicity, indicating favorable biocompatibility. These results suggest that the developed polymeric micelle systems have potential as stable and biocompatible delivery systems for BIC, warranting further investigation."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Efficacy and tolerability of oral bicalutamide in forty postmenopausal women with female pattern hair loss: a retrospective study. (PubMed, Actas Dermosifiliogr) - No abstract available

Journal • Retrospective data • Alopecia

Unresectable Desmoplastic Small Round Cell Tumor: A Case Report and Review of the Literature. (PubMed, Case Rep Oncol) - "We report the case of a 38-year-old male with unresectable intra-abdominal DSRCT treated with the VAC-IE regimen (vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide) as first-line therapy...As second-line therapy, he received gemcitabine and docetaxel...Alternative regimens include temozolomide plus irinotecan or gemcitabine plus doxorubicin. In patients with androgen receptor positivity, hormonal blockade with leuprolide and bicalutamide may be a therapeutic option, particularly in frail patients...DSRCT is a challenging and aggressive malignancy requiring a multidisciplinary and individualized approach. The combination of systemic therapy and local control measures remains critical for improving patient outcomes."

Journal • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • AR • EWSR1 • WT1

Sampling High-Dimensional Conformational Free Energy Landscapes of Active Pharmaceutical Ingredients. (PubMed, J Chem Theory Comput) - "As a key application, we investigate the solvent-dependent conformational preferences of bicalutamide in vacuum, chloroform, and DMSO. The predicted global minima reflect the known solvent-induced conformational shift between open and closed forms, in agreement with NMR and crystallographic data. These results demonstrate that our workflow provides a scalable route to high-dimensional conformational free energy landscapes, with direct relevance for polymorphism, solvation, and drug design."

Journal

Single arm phase II study with abemaciclib and bicalutamide in locoregionally advanced inoperable or metastatic androgen receptor-positive triple-negative breast cancer (ABBICAR) (SABCS 2025) - P2 | "This trial explores a novel, chemotherapy-sparing treatment strategy for AR-positive TNBC. If successful, it could offer a more tolerable alternative to conventional chemotherapy. Results from the first stage are expected in 2026."

Metastases • P2 data • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • AR • ER • RB1

A phase I/II, single arm, non-randomized study of ribociclib, a CDK 4/6 inhibitor, in combination with bicalutamide, an androgen receptor inhibitor, in advanced AR-positive triple-negative breast cancer: A Big Ten Cancer Research Consortium Study (SABCS 2025) - "Although the study did not complete accrual, there were 5 patients with AR+ TNBC treated with ribociclib and bicalutamide combination therapy who achieved disease control at 16 weeks. Further, the AR V7 CTC gene signature may be an emerging biomarker of treatment response to AR and CDK 4/6 inhibition. Future investigation of biomarkers beyond tissue AR IHC staining could be investigated to improve patient selection."

Clinical • Combination therapy • IO biomarker • Metastases • P1/2 data • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • PGR

Efficacy Analysis of ADT+ bicalutamide versus ADT+Novel Hormonal Therapy in Neoadjuvant Therapy for High-Risk/Locally Advanced Prostate Cancer [WITHDRAWN] (ESMO Asia 2025) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A novel disulfidptosis-related lncRNA signature to predict prognosis and immune response of cervical cancer. (PubMed, Medicine (Baltimore)) - "The low-risk group exhibited improved survival outcomes and increased sensitivity to immunotherapy, whereas the high-risk group showed heightened sensitivity to to bexarotene, bicalutamide, embelin, FH535, and pazopanib. Quantitative PCR results indicated that ILF3-DT and PPP1R14B-AS1 were downregulated in CC tissues, whereas RUSC1-AS1 was upregulated. In conclusion, we developed a novel prognostic risk signature based on 9 disulfidptosis-related lncRNAs, which may serve as an independent predictor of immunotherapy response and chemotherapy sensitivity in CC."

Biomarker • IO biomarker • Journal • Cervical Cancer • Oncology • Solid Tumor • PPP1R14B • RUSC1-AS1

Conformational Evolution of Bicalutamide in Chloroform: A Comprehensive NMR Study. (PubMed, Molecules) - "This behavior of conformational evolution contrasts previous understandings of the solid phase's influence on molecular conformation in solution. The results obtained will offer deeper insights into the conformational evolution of small molecules during nucleation, using bicalutamide as a model."

Journal

Elderly Men with De Novo Metastatic Castration-Sensitive Prostate Cancer: Therapy and Does Comorbidity Matter. (PubMed, Medicina (Kaunas)) - "A substantial portion of patients received androgen deprivation therapy (ADT) alone or with bicalutamide despite recommendations for intensified therapy. Enzalutamide was associated with numerically longer survival compared to other treatments, although the difference was not statistically significant. Additionally, the absence of hypertension appeared to be linked with a lower risk of progression, suggesting that comorbid conditions such as hypertension may influence treatment outcomes in elderly patients."

Journal • Retrospective data • Cardiovascular • Genito-urinary Cancer • Geriatric Disorders • Hormone Sensitive Prostate Cancer • Hypertension • Oncology • Prostate Cancer • Solid Tumor

PRESTO: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (clinicaltrials.gov) - P3 | N=504 | Completed | Sponsor: Alliance Foundation Trials, LLC. | Active, not recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Jun 2025

Trial completion • Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Watchful waiting in prostate cancer: Analysis of predictive factors for treatment necessity (EMUC 2025) - "Among patients with metastatic progression, all received androgen deprivation therapy (ADT): four underwent bilateral orchiectomy, two were treated with LHRH agonists (triptorelin) plus a first-generation antiandrogen (bicalutamide), and one received LHRH agonist plus apalutamide. Among the non-metastatic patients who initiated treatment, five underwent orchiectomy, three received LHRH agonists either alone or with bicalutamide, and three were treated with radiotherapy in combination with ADT—one of whom also received abiraterone...Subsequent treatment included enzalutamide in three cases and darolutamide in one...Conclusions In this cohort, WW was safe, with low treatment and progression rates. Histological factors, namely ISUP grade and number of positive cores, were predictive of treatment need, reinforcing their role in initial risk stratification."

Biomarker • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Characteristics of tertiary lymphoid structures in prostate cancer and the impact of neoadjuvant therapy on their formation and maturation. (PubMed, Front Immunol) - "Flow cytometry evaluated immune infiltration in bicalutamide-treated mice, and anti-PD1 was combined with degarelix/bicalutamide in preclinical mouse model. NHT enhances TLS formation, maturation, and immune cell infiltration, suggesting a synergistic role for androgen deprivation in shaping the tumor immune microenvironment. The improved anti-tumor response with combined anti-PD1 and ADT highlights the potential of immunotherapy-endocrine therapy combinations as a promising treatment strategy for PCa."

IO biomarker • Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD20 • CD21 • CD4 • CD8 • FOXP3

Dual drug co-encapsulation into liposomes and liposome-derived nanosystems for improved synergistic treatment of skin diseases. (PubMed, Drug Deliv Transl Res) - "Conventional and modified liposomes, niosomes, transfersomes, ethosomes, invasomes, cerosomes, liposomal gels, and niosomal gels were developed, co-encapsulating synthetic and nature-derived substances such as adapalene, amphotericin B, benzoyl peroxide, bicalutamide, bupivacaine, buprenorphine, curcumin, ginger, glycyrrhetinic acid, metformin, methotrexate, microRNA-21, minoxidil, nicotinamide, Nigella sativa seed oil, pentamidine, psoralen, resveratrol, simvastatin, tocopherol acetate, tretinoin, and virgin coconut oil. By co-encapsulating active substances with distinct mechanisms of action, the developed nanosystems provide synergistic therapeutic effects, leading to reduced toxicity and enhanced bioavailability, potentially resulting in improved clinical outcomes, and presenting a promising alternative to conventional treatments. Through addressing clinical and regulatory framework aspects, these innovative therapies might one day transition from bench to market to..."

Journal • Review • Acne Vulgaris • Alopecia • Dermatology • Immunology • Infectious Disease • Psoriasis • Vitiligo • MIR21

Integrated multi-omic analysis unravels the characteristics of the metabolism-related intratumoral microbes and establishes a novel signature for predicting prognosis and therapeutic response in lung adenocarcinoma. (PubMed, Transl Cancer Res) - "Additionally, a microbial prognostic-predictive signature was established comprising Succinimonas, Collimonas, and Marichromatium, which also exhibited potential for indicating immunotherapeutic benefit and predicting drug sensitivity to cisplatin, cytarabine, pyrimethamine, olaparib, bicalutamide and vorinostat in LUAD treatment. This study identified intratumoral microbes associated with metabolism, revealed distinct subtypes and their roles in LUAD, and established a predictive signature for the prognosis and therapeutic responsiveness of LUAD."

IO biomarker • Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BCL3 • KLF3 • NFKB2

A Balancing Act: Prostate Cancer, Antiandrogen Therapy, and Cardiovascular Disease (KIDNEY WEEK 2025) - "Case Description A 70-year-old male with no comorbidities and high risk, localized PCa was initially treated with Bicalutamide followed by radiation. Three years later due to recurrence abiraterone and prednisone was initiated...BP was refractory to five anti-HTN medications (amlodipine, hydralazine, eplerenone, clonidine, indapamide), which were added over time at tolerated doses...Mineralocorticoid receptor antagonists may interfere with Abiraterone's mechanism of action, limiting their role in treating HTN. Thus Timely recognition of PCa therapy-related side effects is essential to minimize cardiovascular mortality and prevent treatment disruption."

Congestive Heart Failure • Genito-urinary Cancer • Heart Failure • Hypertension • Oncology • Prostate Cancer • Solid Tumor

Unveiling oncogene-induced senescence: a new frontier in prostate cancer prognosis and therapy. (PubMed, Discov Oncol) - "Our study screened seven genes with potential value for predicting long-term survival of patients with PCa and developed a prognostic model. These findings are expected to guide future development of effective therapies."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urology • CDK6 • TMB

Resolution of Radiculopathy from a Large Posterior L2 Mass Following Conservative Management: A Case Report (ASRA-FALL 2025) - "On 11/7/22, the patient began palliative radiotherapy (20Gy in 5 fractions to the upper lumbar spine), prednisone 10mg daily, and bicalutamide 50mg daily. In such cases, high-dose steroids can reduce edema and radiation can induce tumor regression. Early multidisciplinary collaboration was essential in this case, balancing risks of treatment and urgency of symptom relief."

Case report • Clinical • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Prostate Adenocarcinoma • Prostate Cancer

Bicalutamide: A Rare Cause of Drug-Induced Autoimmune Hepatitis (ACG 2025) - "Bicalutamide was discontinued and he was discharged on a prednisone taper...In some cases, patients require additional immunosuppressive therapy, such as azathioprine, to lead to complete resolution in DIAIH...At right, photomicrograph of liver core biopsy showing interface activity composed of plasma cells clusters and occasional eosinophils (Hematoxylin and eosin, 20x).Figure: Figure 2. Photomicrograph of liver core biopsy showing plasma cell clusters (Hematoxylin and eosin, 40x)."

Autoimmune Hepatitis • Fatigue • Hepatitis C • Hepatology • Immunology • Inflammation • Liver Failure • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: OHSU Knight Cancer Institute | N=32 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • IO biomarker • Trial withdrawal • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • PD-L1

A Rare Case of Metastatic Prostate Cancer Causing Obstructive Jaundice (ACG 2025) - "He was on hormone suppressive treatment with bicalutamide and leuprolide. Understanding this should guide clinical decision making and patient goals of care discussions.Figure: Figure 1. CT abdomen/pelvis with IV contrast revealed severe intra- and extrahepatic bile duct dilation with obstruction from adenopathy.Figure: Figure 2.CT abdomen/pelvis with IV contrast revealed extensive bulky retroperitoneal and gastrohepatic adenopathy with bilateral pelvic adenopathy."

Clinical • Metastases • Cholestasis • Constipation • Gastroenterology • Gastrointestinal Disorder • Genito-urinary Cancer • Hematological Malignancies • Hepatocellular Cancer • Hepatology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prostate Cancer • Solid Tumor

Identification and validation of prognostic genes associated with m6A-regulated programmed cell death in acute lymphoblastic leukemia. (PubMed, Sci Rep) - "Sensitivity analysis of 60 chemotherapy agents indicated that Bicalutamide was more effective in LRG, while ATRA, CCT018159, PHA-665752, and PLX4720 demonstrated greater efficacy in HRG. RT-qPCR validation confirmed upregulation of CDK4 and downregulation of CFLAR in ALL samples (P < 0.05). This study offers important theoretical support for the prognostic evaluation and personalized treatment strategies in ALL."

Biomarker • Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CDK4 • CFLAR